[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538004":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":28,"responsibleParty":46,"collaborators":48,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort of patients with mold invasive fungal infection",null,"Patients \\>18 y, with a diagnosis of proven or probable mold invasive fungal infection (Aspergillus, Mucorales, Fusarium or Scedosporium), according to modified 2019 EORTC\u002FMGS criteria, at diagnosis or at a refractory state after a first-line antifungal treatment",[13],{"name":14,"affiliation":15,"role":16},"Fanny LANTERNIER, MD, PhD","APHP","STUDY_CHAIR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Alexandra SERRIS, MD, PhD","CONTACT","06 68 80 24 92","+33","alexandra.serris@aphp.fr",{"name":25,"role":20,"phone":26,"phoneExt":22,"email":27},"Gael PLASTOW, Project advisor","01 44 38 18 57","gael.plastow@aphp.fr",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Hôpital Necker Enfants Malades","RECRUITING","Paris","75015","France",{"type":36,"coordinates":37},"Point",[38,39],2.3488,48.85341,{"lat":39,"lon":38},[42,43,44],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},{"name":25,"role":20,"phone":26,"phoneExt":22,"email":10},{"name":14,"role":45,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":6},"URC-CIC Paris Descartes Necker Cochin","100538004",false,"NCT06285188","Immunomonitoring of Mold Invasive Infections","IMMUNOFIL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium\n* Proven or probable according to 2019 EORTC\u002FMGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria\n* Within 14 days of IFD diagnosis or\n* a refractory state defined by the 2009 MGS\u002FEORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient\n* Patients with aspergillosis or mucormycosis for whom ELISPOTs are developed: Total lymphocyte count \\> 700\u002Fmm3 on the last sample taken\n* No opposition to participate to the research\n* Affiliated or beneficiary of social security system\n\nExclusion Criteria:\n\n* Bacterial co-infection in the last 14 days\n* Previous treatment with anti-PD1 antibodies","ALL","18 Years",{"count":60,"type":61},20,"ESTIMATED","OBSERVATIONAL","Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.",[65,66],"Invasive Fungal Disease","Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium",[68,69,70,71],"Invasive fungal diseases,","adaptative immunity against filamentous fungi","immune checkpoint molecules","anti-PD1","2025-11-17",{"date":74,"type":75},"2025-11-20","ACTUAL",{"date":77,"type":75},"2025-07-28",{"date":79,"type":61},"2027-07",{"name":5,"class":6},1]